Drs. Group Urges FTC Antitrust Scrutiny Of Insulin Pricing

By Bryan Koenig (October 30, 2018, 7:14 PM EDT) -- The American Medical Association wants the Federal Trade Commission to probe potential anti-competitive conduct by drugmakers that may be contributing to the soaring price of insulin, and it encouraged the agency in a recent letter to refer any antitrust violations to the U.S. Department of Justice for enforcement.

In a letter to FTC Chairman Joseph J. Simons dated Oct. 26, AMA Executive Vice President and CEO James J. Madara said physicians in the last few years have become more and more concerned that the "rapid rise" in insulin pricing is unconnected to "the actual costs" going into its development, production or...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!